Laurent Audoly, CEO and president of Kymera Therapeutics, left the Cambridge, Mass., biotech late last month, just weeks after the startup signed a $70 million business deal with Vertex Pharmaceuticals, company executives said Monday.
A news release issued by the privately held company said Audoly “has decided to pursue new entrepreneurial opportunities” but did not elaborate. He has been temporarily succeeded by Nello Mainolfi, a cofounder and the chief scientific officer of the firm.
